BioSpace News Archive

The Leukemia & Lymphoma Society recognized and celebrated the outstanding contributions of five scientific investigators for their achievements in helping drive forward LLS’s work to cure blood cancers and improve the quality of life of patients and their families.

More than 1,100 Community Health Centers - also called Federally Qualified Health Centers, or FQHC - provide affordable, comprehensive care to over 30 million children and adults across the United States.

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced positive updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies.

Predicine, Inc., a leading molecular insights company, announced a significant clinical milestone with the new publication of Genentech’s Divarasib plus Cetuximab study in Nature Medicine.

Sutro Biopharma, Inc. today announced that its research collaborators presented data on anti-leukemic activity from the compassionate use of luveltamab tazevibulin (luvelta), a novel folate receptor-α (FR-α) targeting ADC, in pediatric patients with relapsed/refractory CBFA2T3-GLIS2 (CBF/GLIS) acute myeloid leukemia (AML), commonly known as RAM phenotype AML.

Leap Therapeutics, Inc. today announced that the Company will be presenting new data in second-line patients with advanced colorectal cancer from the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap’s anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

Sanofi is disappointed with the Federal Trade Commission’s announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics.

Inotiv, Inc. (Nasdaq: NOTV) (the “Company”) today announced financial results for the three months (“Q4 FY 2023”) and twelve months (“FY 2023”) ended September 30, 2023.

New research in the December 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds patients treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer showed similar results in terms of survival, progression-free survival, and treatment duration, regardless of race or ethnicity, even with differences in income and insurance.

Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the National Academies of Sciences, Engineering, and Medicine Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures public meeting on Thursday December 14, 2023.